← Back to all trials
Recruiting
NCT06927635
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Conditions: Castrate Resistance Prostate Cancer, OligoProgressive Metastatic Disease
Sex: Male
Ages: 18 Years – 100 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 75
Sponsor: University Health Network, Toronto
Location: Princess Margaret Cancer Center Toronto Ontario
Summary
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
Eligibility Criteria
Inclusion Criteria:
* Age \>18 years
* Able to provide informed consent
* Histologic diagnosis of prostate adenocarcinoma
* Castrate Resistance Prostate Cancer
* Radiographic evidence of \3 months
* All sites of OP disease are amenable to and can be safely treated with SBRT
* ECOG performance status 0-3
Exclusion Criteria:
* Evidence of spinal cord compression
* Contraindication to radiotherapy
Source: ClinicalTrials.gov (NCT06927635). StuddyBuddy aggregates publicly available trial information.
